egnite, Inc. Announces A.I. Partnership with Leading Physicians to Elevate the Standard of Care for Patients with Cardiovascular Disease

egnite, Inc. Announces A.I. Partnership with Leading Physicians to Elevate the Standard of Care for Patients with Cardiovascular Disease

Partnership leverages egnite’s artificial intelligence and big data expertise with Philippe Généreux and Linda Gillam from Morristown’s world-class Gagnon Cardiovascular Institute

ALISO VIEJO, Calif. – February 27, 2023 –  egnite, Inc., a digital healthcare company, announces a partnership with leading physicians from Morristown’s Gagnon Cardiovascular Institute, Philippe Généreux, a Director of the Structural Heart Program, and Linda Gillam, Chair of Cardiovascular Medicine. This partnership aims to elevate the standard of care for patients with cardiovascular (CV) disease, which affects an estimated 126 million adults in the U.S. and is expected to increase by 30% by 2060.

The partnership will spearhead research initiatives to better understand optimal points of therapeutic intervention for patients with valvular heart disease, using egnite’s flagship digital health platform, CardioCare. This initiative furthers the use of precision medicine algorithms to help physicians design and deliver an individualized patient management plan.

“CardioCare’s AI tools will help us ensure that every patient receives optimal evaluation and management of their heart disease,” says Gillam, adding, “Its big data approach will also help us identify patients who might be candidates for one of many research trials, thereby potentially giving patients access to otherwise unavailable therapeutic options.”

“We are honored to be partnering with Doctors Gillam and Généreux, and working with physicians of this caliber will help us accelerate our platform’s innovation,” said Joel Portice, president and CEO of egnite.

The partnership will also support the expansion of Dr. Généreux’s staging research, which examines the value of cardiac staging relating to the treatment and outcomes of AS & MR using the 12 million de-identified cardiovascular encounters in egnite’s database.

“I am thrilled to collaborate with egnite’s team and use their incredible platform to better understand valve disease, build meaningful research, and improve patient management and outcomes,” said Généreux.

About egnite, Inc.

egnite is a visionary digital health company committed to advancing the health of our society through innovative cardiovascular solutions. egnite uses AI-driven algorithms and big data to produce business intelligence for healthcare, elevating the role of data in critical decisions. The company partners with leading hospitals and life sciences organizations to transform care delivery for cardiovascular patients. The company is based in Aliso Viejo, Calif., for more information, visit www.egnitehealth.com.

Related Articles

egnite Research

SGLT2i + GLP-1 RA: A Dynamic Duo in HFpEF?

Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.

Figure 1: Observed Mortality Stratified by GLP-1 RA and/or SGLT2i Prescription
egnite Research

Two-Year Mortality Following Heart Failure Hospitalization in Patients with HFpEF Stratified by SGLT2i and GLP-1 RA Therapy: A Real-World Analysis

BACKGROUND Heart failure with a preserved ejection fraction (HFpEF) is characterized by frequent hospitalizations, and substantial mortality. While historically lacking effective therapies, newer treatments, including SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA), have shown potential benefits. However, the clinical course of HFpEF under these therapies remains incompletely characterized,

egnite Research

What the EARLY TAVR Trial Data Could Mean for Already Busy Heart Teams 

On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.